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Summary
Current guidelines from the Swiss Association against Os-
teoporosis (SVGO) dating from 2015 recommend therapy
for men and women at increased fracture risk, specifically
those with a vertebral or hip fracture; those with bone min-
eral density T-score <−2.5 at spine or hip; and those with a
high 10-year probability of a major osteoporotic fracture as
calculated by using FRAX. However no specific treatment
recommendations have been made so far in our country
to guide therapy according to the baseline level of risk. We
now define four risk subgroup categories (imminent and
very high, high, moderate, low) and propose an algorithm
for osteoporosis therapy according to the level of fracture
risk.
Keywords: osteoporosis, fragility fractures, bone mineral
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Introduction
In Switzerland, one woman in two and one man in five will
sustain a fragility fracture after the age of 50. Hence the
number of incident fragility fractures is at least 75,000 per
year; 140,000 subjects have prevalent hip or vertebral frac-
tures and 450,000 have osteoporosis (in 2010) [1]. In turn,
the acute complications of osteoporosis are a major cause
of hospitalisations and the chronic complications, such as
the loss of mobility and independence in daily living ac-
tivities, increase the needs for secondary care and nursing
homes. Yet primary and secondary prevention of fragili-
ty fractures remains insufficient, as it is estimated that less
than 10% of subjects with osteoporosis and only 20% of
subjects with low-trauma fractures receive anti-osteoporot-
ic medications [2]. Hence identification and treatment of
subjects at high risk of fragility fractures remains critical.
Current guidelines from the Swiss Association against Os-
teoporosis (SVGO) dating from 2015 recommend therapy
for men and women at increased fracture risk, specifically
those with a vertebral or hip fracture; those with bone min-
eral density (BMD) T-score <−2.5 at spine or hip; and
those with a high 10-year probability of major osteoporotic
fractures calculated by using the fracture risk assessment
tool FRAX . By high risk we mean at least equivalent to
the 10-year risk of an individual of the same age and sex
with a prevalent vertebral fracture, which in Switzerland
corresponds to about 10% by age 50 years and 30% by
age 72 years (fig. 1). In addition, patients receiving chronic
glucocorticoid therapy, anti-aromatase therapy or androgen
suppression therapy are also considered at high risk and
recommended for osteoporosis treatment. More recently,
SVGO also made recommendations regarding the duration
and the sequence of osteoporosis therapy [3]. In partic-
ular, it was recommended that high risk patients, includ-
ing those older than 65 yrs and fallers remain treated until
reaching a bone mineral density (BMD) at hip better than
−2.0 T-score.
There are multiple classes of drugs available for the treat-
ment of osteoporosis and fracture prevention, including:
Figure 1: Intervention thresholds for osteoporosis therapy based
on the 10-year risk of a major osteoporotic fracture in Switzerland.
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antiresorptives, namely, selective oestrogen receptor mod-
ulators (SERMs: raloxifene, basedoxifene), bisphospho-
nates (alendronate, risedronate, ibandronate, zoledronate)
and monocloncal antibodies (denosumab); bone forming
agents (teriparatide); and, very recently approved in
Switzerland, a new monoclonal antibody, romosozumab,
with dual antiresorptive and anabolic effects. As stated
in the 2015 SVGO guidelines: “In general an anti-resorp-
tive (AR) is recommended as first line (without specifying
whether and when it should be SERMs, bisphosphonates
or denosumab), whereas teriparatide (TPT) could be rec-
ommended as first line in case of severe osteoporosis (i.e.,
BMD <−2.5 + vertebral fracture).”
However, no specific treatment recommendations have
been made so far in our country to guide therapy according
to the baseline level of risk. Here we provide new guidance
to categorise patients at various levels of risk based on
their probability of a major osteoporotic fracture (rather
than hip fracture only, which accounts for only a fraction
of the former) and to choose the most appropriate first-line
therapy for each risk category.
New evidence regarding patients at very high
and/or imminent risk
Recent publications have provided new evidence regarding
the identification of very high risk patients and the efficacy
of certain treatments in this population. First, patients with
a recent major osteoporotic fracture (spine, hip, pelvis,
humerus or radius) are increasingly recognised as being at
“imminent risk”, since the relative risk of a second fracture
is increased several fold within the first 2 years after the
index fracture but declines thereafter, and 40% to 60% of
all recurrent fractures will occur within those 2 years [4].
According to some very recent Medicare data from the US,
after 65 years of age, 25% of patients with a vertebral frac-
ture and 15% or more of those with a hip or pelvis frac-
ture will refracture within 2 years, whereas 10% or more of
those with humerus or distal radius fractures will refracture
within 2 years [5].
An important consequence of identifying subjects with re-
cent fractures is the positive impact it has on the cost-bene-
fits of therapy. Indeed, by taking into account the imminent
risk of refracturing in these subjects, the number of sec-
ondary fractures potentially prevented by treatment would
be doubled compared with subjects with similar fractures
but in whom the recentness of the fracture has not been tak-
en into account [6]. Moreover, it has been estimated that in
these imminent-risk patients, parenteral therapy with deno-
sumab, teriparatide or romosozumab would prevent more
fractures than using an oral bisphosphonate [6].
Two recent major head-to-head trials have demonstrated
the greater anti-fracture efficacy of teriparatide and ro-
mosozumab compared with oral bisphosphonates (rise-
dronate and alendronate) in high-risk subjects defined by
severe and/or multiple vertebral fractures (VERO [7] and
ARCH [8], respectively). Notably, romosozumab also sub-
stantially increased BMD at spine and hip within 1 year
and significantly more so than bisphosphonates or teri-
paratide [8, 9]. However, its benefits and risks should be
evaluated carefully in patients at higher cardiovascular
risk, since romosozumab was associated with more car-
diovascular serious adverse events than alendronate in one
study [8].
Accordingly, the International Osteoporosis Foundation
(IOF) jointly with the European Society for the Clinical
and Economic Aspects of Osteoporosis (ESCEO) have re-
cently proposed an algorithm for the management of pa-
tients at low, high and very high risk of osteoporotic frac-
tures, in which they still recommend a potent
anti-resorptive (bisphosphonate or denosumab) in high-
risk patients, but consideration of an anabolic agent (teri-
paratide, romosozumab) first in very high-risk patients
[10]. In women with a recent major osteoporotic fracture,
use of an anabolic drug for a short period (12–18 months)
followed by an anti-resorptive over a total duration of ther-
apy of 10 years would result in more fractures saved than
use of an anti-resorptive followed by an anabolic drug over
the same period [10].
Based on these new developments, we now delineate the
various risk categories and recommended treatments for
each level of risk in order to facilitate the management
of osteoporosis in Switzerland, notwithstanding the current
limitations for reimbursement of some drugs in our coun-
try.
Risk stratification
– Risk stratification should take into consideration previ-
ous fragility fractures, BMD, age and other clinical risk
factors as encompassed in FRAX (table 1). Moreover,
the risk of falls should be taken into consideration, as
subjects with risk factors for falls (such as >1 fall in past
year, Parkinson’s disease, urinary incontinence, etc.)
may have a fracture risk that is nearly double that of in-
dividuals with similar bone risk profiles but without
falls [11].
– In patients at risk, BMD should be evaluated at spine
and hip using dual energy X-ray absorbtiometry
(DXA). When possible, a vertebral fracture assessment
and trabecular bone score by DXA could also be per-
formed to further refine the risk evaluation.
– Bone turnover markers, particularly carboxy terminal
crosslinked telopeptides of type 1 collagen (CTx) and
procollagen type 1 N-terminal propeptide (P1NP), are
not recommended for risk stratification. However they
may be useful to guide treatment decisions in some risk
categories (below) and to monitor treatment efficacy in
all categories.
– Subjects should be considered at imminent risk (i.e.,
>10% fracture risk within 2 years) if they have suffered
Table 1: Clinical risk factors for fractures in FRAX.
Age
Sex
Body mass index
Previous fracture
Parental hip fracture
Current smoking
Alcohol >3 units/d
Glucocorticoids
Rhumatoid arthritis
Secondary osteoporosis (type 1 diabetes, malabsorption, chronic liv-
er disease, hypogonadism, untreated hyperthyroidism, adult osteo-
genesis imperfecta)
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a recent (<2 years) clinical vertebral or low-trauma hip
fracture, or any recent major osteoporotic fracture (in-
cluding humerus, radius, pelvis) after the age of 65.
– Subjects should be considered at very high risk when
their 10-year probability of major osteoporotic fracture
according to FRAX is at least 20% absolute risk above
the intervention threshold at any age (fig. 1). This
would correspond to a 10-year FRAX probability of
about 50% after the age of 70, equivalent to an immi-
nent risk of 10% within 2 years (above).
– For instance, a 55-year-old woman with a previous
wrist fracture, body mass index (BMI) 20 kg/m2,
who smokes, whose mother had a hip fracture, and
whose hip BMD is −2.7 T-score would reach the
very high risk threshold for her age (FRAX proba-
bility 34%). Another example would be a 70-year-
old woman with a previous vertebral fracture, on 5
mg/d prednisone for a chronic inflammatory disor-
der, hip BMD −3.1 T-score (FRAX probability
46%).
– Subjects with previous major osteoporotic fractures (>2
years) and/or FRAX probabilities above the interven-
tion threshold but less than 20% above that limit (fig. 1)
should be considered high risk, irrespective of their
BMD level (since more than 50% of fragility fractures
occur in subjects with BMD levels ≥−2.5 T-score).
– Subjects receiving chronic glucocorticoid, aromatase
inhibitor or androgen suppression therapy should also
be considered high risk if their BMD is <1.5 T-score
and/or FRAX probability above the intervention thresh-
old (fig. 1).
– Subjects with BMD <−2.5 T-score but no previous frac-
ture and a FRAX probability below the intervention
threshold should be considered at moderate risk.
– Subjects with osteopenia (T-score >−2.5 and <−1.0) and
no other risk factors should be considered at low risk.
Treatment by risk category
Despite numerous studies comparing the effects of various
treatments on BMD changes, only a few trials, including
the VERO and ARCH trials mentioned above, directly
compared the anti-fracture efficacy of osteoporosis drugs
in high-risk patients [7, 8, 12], and none has compared an-
abolics with the most potent anti-resorptives (zoledronate
and denosumab). Moreover, a single trial specifically re-
cruited patients with a recent hip fracture, hence at immi-
nent risk, and demonstrated that a yearly infusion of zole-
dronate initiated within 3 months after the fracture reduced
secondary clinical fractures by 32% and mortality by 25%
compared with placebo (median follow-up 1.9 years) [13].
Post-hoc analyses of the FREEDOM trial also reported
that denosumab significantly reduced vertebral and hip
fractures in high risk subjects (>75 yrs, hip T-score <−3.0,
previous fracture) [14]. Denosumab has also been shown
to reduce fracture risk in other high-risk categories, namely
in postmenopausal women with early breast cancer receiv-
ing an aromatase inhibitor [15], as well as in men with non-
metastatic prostate cancer receiving androgen suppression
therapy [16].
Treatment recommendations for the various risk categories
are shown in figure 2 and explained below.
– In patients at imminent / very high risk with a vertebral
fracture, teriparatide for 18–24 months is recommend-
ed (in absence of formal contraindications such as re-
Figure 2: Treatment recommendations by level of risk. SERMS = selective oestrogen receptor modulators; BPs = bisphosphonates; Zol =
zoledronate; TPT = teriparatide. Dashed lines indicate alternative treatments (see text for details).
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cent cancer / radiation therapy to the skeleton), fol-
lowed by an anti-resorptive (bisphosphonate or deno-
sumab)
– In patients at imminent / very high risk with a hip frac-
ture, zoledronate once yearly is recommended when re-
nal function is not compromised (creatinine clearance
>35 ml/min). Alternatively, consider denosumab.
– -– In all patients at imminent / very high risk, ro-
mosozumab is also recommended as first-line therapy
for 1 year, followed by an anti-resorptive (bisphospho-
nate or denosumab), potentially excluding patients with
recent cardiovascular events and/or at high cardiovas-
cular risk
– In high-risk patients, including those on glucocorti-
coids, aromatase inhibitors or androgen suppression
therapy, a potent anti-resorptive is recommended (note
that denosumab is not approved for glucocorticoid-in-
duced osteoporosis). Alternatively, consider teri-
paratide if there is a vertebral fracture or spine BMD
<−3.5 T-score [17], but taking into consideration the
contraindications to teriparatide in some cancer pa-
tients.
– In moderate-risk subjects who do not receive oestrogen
replacement therapy, consider SERMS, eventually oral
bisphosphonates if bone turnover markers such as CTx
and P1NP are above the premenopausal threshold.
– In all the above categories, repeat DXA after 2 years
and reevaluate fracture risk before deciding on pursuing
treatment
– In low-risk subjects, recommend life style measures, vi-
tamin D supplements (800–1000 IU/d) ± calcium
(500–1000 mg/d) if necessary, and repeat DXA after
5–10 years or if clinical risk increases.
Discussion
These new recommendations on osteoporosis treatment
differ from the previous SVGO guidelines (2015) by fur-
ther defining four risk categories, including a new one –
imminent and very high risk. Furthermore, among the ar-
mamentarium of osteoporosis drugs available, newly en-
riched by a potent anabolic agent with dual anti-resorptive
properties, romosozumab, we now delineate which drugs
should be used to inititate therapy according to the fracture
risk category. In defined patients at imminent / very high
risk in particular, a more aggressive approach with bone
forming agents or anabolics is now recommended as first-
line therapy, although some reimbursement issues may still
be present. By recommending specific classes of drugs ac-
cording to the level of fracture risk, we hope to facilitate
the decision making of all doctors involved in the manage-
ment of osteoporosis and thereby to narrow the treatment
gap for this common disease. Nevertheless, we acknowl-
edge that the threshold for “very high risk” as defined here
is somewhat arbitrary. We intentionally chose a threshold
for very high risk that is quite elevated in order to keep the
size of the targeted population relatively limited, in consid-
eration of the potential risks and/or higher costs of anabol-
ic agents. The recent development of teriparatide biosim-
ilars may actually favour its use among imminent / very
high risk subjects. To note that, using a lower “very high
risk” threshold in the UK population, it has been estimated
that only about 15% of post-menopausal women will fall
into that category at any age [10]. We therefore expect that
only 10% or less of post-menopausal women in Switzer-
land will fall into that category. Further studies are need-
ed in Switzerland and elsewhere to evaluate whether such
threshold captures a sufficient proportion of subjects effec-
tively at very high risk, or on the contrary is too restrictive,
which would call for adapting our guidelines in the future.
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